Treatment for mesothelioma typically involves a combination of immunotherapy, chemotherapy, surgery, and radiation, with the specific plan depending on the tumor’s cell type, how far the disease has spread, and overall health. The five-year survival rate across all stages is about 15%, but newer treatment combinations are improving outcomes significantly compared to a decade ago.
First-Line Treatment: Immunotherapy
Immunotherapy has become a frontline option for mesothelioma that cannot be surgically removed. The most established regimen pairs two checkpoint inhibitor drugs that help your immune system recognize and attack cancer cells. In the landmark CheckMate 743 trial, this combination extended median survival to 18.1 months, compared to 14.1 months with chemotherapy alone. Perhaps more telling, 41% of patients on immunotherapy were alive at two years versus 27% on chemotherapy.
Current ASCO guidelines, updated in 2024, recommend immunotherapy as the preferred first-line treatment for all newly diagnosed mesothelioma. For nonepithelioid subtypes (the more aggressive forms), guidelines go further: chemotherapy alone should not be offered unless there’s a medical reason a patient can’t receive immunotherapy. In September 2024, the FDA also approved a newer option combining immunotherapy with chemotherapy as a first-line treatment for advanced or metastatic disease, giving oncologists more flexibility in tailoring treatment.
Chemotherapy
Chemotherapy remains an important part of treatment, either on its own for certain tumor types or combined with immunotherapy. The standard regimen pairs two drugs given intravenously on the first day of a 21-day cycle. Treatment continues in these three-week rounds until the disease stops responding or side effects become unmanageable.
For epithelioid mesothelioma, the most common and slower-growing subtype, chemotherapy with or without a drug that blocks blood vessel growth to the tumor is a valid first-line option. Before starting treatment, you’ll begin taking folic acid supplements daily and receive a vitamin B12 injection. These aren’t optional extras. They reduce the risk of serious side effects like dangerously low blood counts and mouth sores. You’ll also take a short course of a steroid around each infusion day to limit nausea and allergic reactions.
Surgery for Mesothelioma
Not everyone with mesothelioma is a candidate for surgery, but for those whose tumors can be reached and whose lungs and heart are strong enough, it can significantly extend survival. The two main operations differ in how aggressively they remove tissue.
The less radical approach strips the diseased lining from around the lung while leaving the lung itself intact. The more aggressive procedure removes the entire affected lung along with its surrounding lining, part of the diaphragm, and nearby tissue. For a long time, removing the whole lung was considered the more definitive surgery, but evidence has shifted. One study of patients with disease in both chest cavities found that the lung-sparing surgery was associated with a median survival of 58.2 months, compared to 13.5 months for full lung removal. These were highly selected patients, but the trend toward preserving the lung whenever possible is now well established.
Surgery is almost always combined with other treatments. Radiation or chemotherapy before or after the operation helps target microscopic disease that surgery can’t reach.
Radiation Therapy
Radiation for mesothelioma serves two roles: it can target residual disease after surgery, and it can help control symptoms like chest wall pain. Because mesothelioma wraps around the lung in an unusual pattern rather than forming a single lump, delivering radiation precisely is challenging.
Proton beam therapy has gained traction for mesothelioma because it deposits energy more precisely, sparing the heart and opposite lung from unnecessary exposure. Typical treatment delivers around 50 to 55 units of radiation dose spread over daily sessions of smaller increments. Some centers push higher when the tumor is particularly stubborn or in a location where tighter targeting is possible. Radiation is rarely used as a standalone treatment for mesothelioma. Its greatest value comes as part of a multimodal plan alongside surgery or systemic therapy.
Tumor Treating Fields
A newer, non-drug option uses low-intensity electric fields delivered through adhesive pads worn on the chest. These fields interfere with cancer cell division without affecting normal cells in the same way. In a phase 2 trial, patients who wore the device continuously while also receiving standard chemotherapy had a median survival of 18.2 months, which compares favorably with chemotherapy alone. The device is portable, so treatment happens at home rather than in a clinic. The main downside is skin irritation where the pads sit, and you need to wear them for the majority of each day to get the benefit.
Peritoneal Mesothelioma Treatment
About 10 to 15% of mesothelioma cases develop in the lining of the abdomen rather than the chest. Treatment follows a different path. The standard approach combines extensive surgical removal of visible tumor with heated chemotherapy delivered directly into the abdominal cavity during the same operation. This technique bathes the surgical site in warm chemotherapy solution, targeting microscopic cancer cells left behind.
Five-year survival for patients treated this way reaches about 50%, with a median survival of 40 months. That’s considerably better than the outlook for pleural mesothelioma, partly because the abdominal form tends to be diagnosed with a cell type that responds better to treatment. Recovery from this combined surgery is significant, as it’s a major abdominal operation, but for eligible patients the survival benefit is substantial.
Managing Fluid Buildup
One of the most common and distressing symptoms of pleural mesothelioma is fluid accumulating between the lung and chest wall, causing progressive shortness of breath. Managing this fluid is a critical part of treatment regardless of what other therapies you’re receiving.
A small, tunneled drainage catheter can be placed as an outpatient procedure. You or a caregiver drain the fluid at home, typically every few days. In a study of mesothelioma patients, 57% had excellent relief of breathlessness and another 39% had partial relief. Nearly half of patients experienced spontaneous sealing of the space (so fluid stopped returning) after an average of about 75 days, with some achieving this in as little as two weeks. The alternative is a procedure that intentionally irritates the space to seal it shut, though trapped lung from tumor growth can make that less effective in mesothelioma specifically.
Survival by Stage
How well treatment works depends heavily on how far the disease has spread at diagnosis. Based on data from patients diagnosed between 2015 and 2021, the five-year relative survival rate for localized pleural mesothelioma is 23%. For regional disease that has spread to nearby lymph nodes or structures, that drops to 15%. Distant disease, where cancer has spread to other organs, has an 11% five-year survival rate.
These numbers predate the widespread use of immunotherapy as a first-line treatment, so outcomes for patients diagnosed today may be somewhat better. Current guidelines also recommend that all patients with mesothelioma undergo genetic testing, as certain inherited mutations can influence both treatment choices and screening for family members.